Bastu Odoka: Closing the Gap on Anti-D Prophylaxis in Maternal Care
Bastu Odoka, Transfusion Scientist at Effia-Nkwanta Regional Hospital, shared a post on LinkedIn:
“Anti-D Prophylaxis: A Preventable Gap in Maternal Care
In a recent pre-print review:
- 39 RhD-negative mothers with previous pregnancies
- Only 13 received Anti-D prophylaxis
- 3 of the 13 later developed anti-D antibodies
This is not about blame. It is about systems.
Why Anti-D matters
Anti-D immunoglobulin prevents RhD alloimmunisation when:
- The mother is not already sensitised
- It is administered at routine antenatal timing (around 28 weeks per protocol)
- It is given within 72 hours postpartum when indicated
- All sensitising events are recognised and treated
- Appropriate dosing is used (including for significant fetomaternal haemorrhage)
- Antibody screening (Indirect Antiglobulin Test) is properly documented
If Anti-D is given late, after sensitisation has already occurred, or in inadequate dose, it will not prevent alloimmunisation.
Why this matters clinically
Missed or delayed prophylaxis can lead to:
- Preventable maternal sensitisation
- Haemolytic disease of the fetus and newborn (HDFN)
- High-risk future pregnancies
- Increased neonatal morbidity and healthcare costs
Prevention is safer and far more cost-effective than managing severe neonatal complications.
A systems opportunity in Ghana and similar settings
Strengthening Anti-D access and standardisation could significantly reduce preventable alloimmunisation.
Potential areas for improvement:
- National bulk procurement to ensure consistent availability and reduce unit cost
- Inclusion of Anti-D under NHIS to remove financial barriers
- Development or update of a clear national guideline to standardise timing, dosing, documentation and follow-up
- Strengthening routine antibody screening and documentation practices
This is not only a laboratory issue. It is a maternal and neonatal safety priority.
Preventable alloimmunisation should not become a lifelong risk for mothers when effective prophylaxis exists.
Strong systems protect mothers.
Strong policies protect future generations.”
Stay updated with Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation